---
title: "Changping AI Founder Guide"
canonical: "https://www.cybernomadchina.com/changping-ai-life-sciences-founder-guide"
topic:
  - "AI drug discovery"
  - "multi-omics"
  - "medical AI"
  - "synthetic biology"
  - "research commercialisation"
geography:
  - "Changping"
  - "Zhongguancun Life Science Park"
  - "life-science companies"
evidence:
  - "official source review"
  - "editorial synthesis"
last_reviewed: "2026-08-26"
operator: "Meridian Flow LLC"
primary_language: "en"
---

Content build ID: CN-20260826T1301-8a36f069


# Changping AI Founder Guide

## Purpose

Route AI-bio founders toward the biological, clinical and commercial infrastructure their model must eventually meet.

## Audience

- AI biotech founders
- drug-discovery teams
- medical AI and device builders

## Technology / industry topics

- AI drug discovery
- multi-omics
- medical AI
- synthetic biology
- research commercialisation

## Important distinctions

- Policy existence does not establish programme eligibility.
- A maximum support amount is not an automatic payment.
- Company registration, work authorisation and residence are separate questions.
- Registration Node, Operating Node and Living Base may differ, subject to actual-operation and programme rules.

## Life Science Park is the anchor

Changping's ecosystem joins specialised carriers with pharmaceutical companies, research hospitals, diagnostics, clinical researchers, device engineers, CROs and laboratory partners.

Status: infrastructure  
Last reviewed: 2026-08-26

- Source ref: cp-life-science-2026 — [Changping Medical and Health Industry / AI + Life Science Measures](https://www.beijing.gov.cn/zhengce/zhengcefagui/202605/t20260525_4665432.html)

## AI + healthcare is formal industrial policy

Current measures cover healthcare and multi-omics datasets, specialised biopharma compute, life-science and pharmaceutical models, AI drug discovery, diagnostics, medical devices and synthetic biology.

Status: current policy  
Last reviewed: 2026-08-26

- Source ref: cp-life-science-2026 — [Changping Medical and Health Industry / AI + Life Science Measures](https://www.beijing.gov.cn/zhengce/zhengcefagui/202605/t20260525_4665432.html)

## Policy addresses scientific result → company

The programme includes proof-of-concept, technology transfer and commercialisation routes relevant to research spinouts and scientific IP.

Status: current policy  
Last reviewed: 2026-08-26

- Source ref: cp-life-science-2026 — [Changping Medical and Health Industry / AI + Life Science Measures](https://www.beijing.gov.cn/zhengce/zhengcefagui/202605/t20260525_4665432.html)

## Industrial fit does not remove health-sector regulation

Clinical data, ethics, pharmaceuticals, medical devices, biosafety, IP and research agreements remain separate feasibility layers.

Status: editorial assessment  
Last reviewed: 2026-08-26

- Source ref: cp-life-science-2026 — [Changping Medical and Health Industry / AI + Life Science Measures](https://www.beijing.gov.cn/zhengce/zhengcefagui/202605/t20260525_4665432.html)

## Common questions this page helps answer

- If the model succeeds, who validates the biology?
- Which clinical, laboratory or manufacturing counterpart is required?
- Which regulated conclusion needs a qualified specialist?

## Related CyberNomad pages

- [AI for Science in Beijing](https://www.cybernomadchina.com/beijing-ai-for-science)
- [Huairou AI for Science Guide](https://www.cybernomadchina.com/huairou-ai-for-science-founder-guide)
- [Founder Fit Check](https://www.cybernomadchina.com/founder-fit-check)